Brain Metastases from Endometrial Carcinoma

Cormio, Gennaro; Lissoni, Andrea Alberto; Losa, Gabriele A.; Zanetta, Gerardo; Pellegrino, A.; Mangioni, Costantino

doi:10.1006/gyno.1996.0093

Cited by 81 publications

(106 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Brain involvement in EC is rare and is usually considered a late event. In the series reported in the literature, the incidence of brain metastases ranges from 0.3-0.9% [11,14,15,22,23,50], which is in accordance with the value of 0.6% (10/1610) in our group of patients.…”

Section: Discussionsupporting

confidence: 73%

“…In agreement with the reports of other authors, in the treatment of our group of patients with HM to the brain, surgery, stereotactic radiotherapy, WBPR, and WBRT were used [14,15,18,22,26,32,33,36,38,43,46,49,50]. The median survival of 10 patients was 4 months (range, 1-68 months); 2 patients treated with surgical resection and WBRT survived 60 months.…”

Section: Hm To the Brainsupporting

confidence: 74%

“…The median survival of 10 patients was 4 months (range, 1-68 months); 2 patients treated with surgical resection and WBRT survived 60 months. The data from the literature shows that patient survival after the diagnosis of HM to the brain is poor, with a median survival time of usually less than 2 months (range, 0.2-83 months) [2,14,15,22,33,45]. Long-term survival is rare but has been documented in some patients with solitary brain lesions who underwent surgical resection and WBRT [15,32,43,45,50].…”

Section: Hm To the Brainmentioning

confidence: 99%

See 2 more Smart Citations

Hematogenous metastases in patients with Stage I or II endometrial carcinoma

et al. 2011

View full text Add to dashboard Cite

Hormonal therapy and chemotherapy play a major role in the palliative management of patients with hematogenous metastases from endometrial carcinoma to the liver, lungs, and bones. Radical treatment in patients with metastases to the lung or liver consists of resection of the metastasis combined with chemo- and/or hormonotherapy for metastases to the bones treatment consists of radiotherapy + chemotherapy, for metastasis to the brain treatment consists of resection combined with radiotherapy.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Hm To the Brainsupporting

confidence: 74%

Section: Hm To the Brainmentioning

confidence: 99%

See 1 more Smart Citation

Hematogenous metastases in patients with Stage I or II endometrial carcinoma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Endometrial adenocarcinoma is the most common gynecologic malignancy and has a low incidence of metastasis to the brain, ranging from 0.3% to 1.4% [15,16].…”

Section: Discussionmentioning

confidence: 99%

Brain Metastases in a Patient with Ovarian Cancer

Kabulo¹

2017

IJNPT

View full text Add to dashboard Cite

Abstrat: Brain metastases are associated with a poor prognosis. Depending on the patient's age, functional status, extent of systemic disease, and number of metastases. We report a case of 22-year-old female who presented with 2 months history of headache and vomiting and 1 day history of not communicating, neck stiffness, and generalized body weakness. Patient has been unwell for 2 months after she had collapsed at school 2 months prior complaining of severe headache, she allegedly stroked one month prior with left sided weakness. No history of trauma and seizures but had history of falling and remaining unconscious for unspecified period of time. No history of chronic illness and no family history of malignancies. Brain CT scan and MRI documented multiple lobulated irregularly enhancing brain parenchymal mass lesions of variable sizes, patient was taken to theatre and burr hole for brain tumor biopsy was done and specimen taken for histology which confirmed metastatic carcinoma and the tumor immunoreacted negatively to TTF1 and positively to CK7. Treatment of brain metastasis has evolved over the years from WBRT only for most patients to multimodal therapy including surgical resection, if feasible, followed by Whole brain Radiotherapy (WBRT) and/or chemotherapy.

show abstract

“…ECs spread primarily to the pelvic and para-aortic lymph nodes, and to the adnexa and omentum [98,99]. Distant metastases, for example to the brain [100,101], lungs [102,103,104], or bones [105,106], have also been described. Moreover, this cancer type can incidentally metastasize to the scalp [107], iris [108], mandible [109], pleura [110], or to the pancreas [111].…”

Section: Loh At Tp53 Locus In Metastatic Ecsmentioning

confidence: 99%

Prevalence of Allelic Loss at <i>TP53</i> in Endometrial Carcinomas

Semczuk

Schneider‐Stock²,

Szewczuk³

2010

Oncology

View full text Add to dashboard Cite

Alterations within the TP53 tumor suppressor belong to the most common genetic features reported in various human neoplasms, including endometrial cancer. In this article, the prevalence of allelic loss at the TP53 locus in primary human endometrial carcinomas (ECs) is discussed. Furthermore, we reviewed the role of allelic imbalance at 17p13.1 in metastatic human ECs on the basis of a literature review and on recently published data ascertained by our laboratory staff.

show abstract

Brain Metastases from Endometrial Carcinoma

Cited by 81 publications

References 3 publications

Hematogenous metastases in patients with Stage I or II endometrial carcinoma

Hematogenous metastases in patients with Stage I or II endometrial carcinoma

Brain Metastases in a Patient with Ovarian Cancer

Prevalence of Allelic Loss at <i>TP53</i> in Endometrial Carcinomas

Contact Info

Product

Resources

About